BRPI0715888A2 - composto ou sal farmaceuticamente aceitÁvel do mesmo, composiÇço farmacÊutica, uso de um composto, e, mÉtodos para produzir um efeito inibitàrio de mtor e um efeito anti-cÂncer em um animal de sangue quente e para tratar doenÇas em um animal de sangue quente - Google Patents

composto ou sal farmaceuticamente aceitÁvel do mesmo, composiÇço farmacÊutica, uso de um composto, e, mÉtodos para produzir um efeito inibitàrio de mtor e um efeito anti-cÂncer em um animal de sangue quente e para tratar doenÇas em um animal de sangue quente

Info

Publication number
BRPI0715888A2
BRPI0715888A2 BRPI0715888-2A2A BRPI0715888A BRPI0715888A2 BR PI0715888 A2 BRPI0715888 A2 BR PI0715888A2 BR PI0715888 A BRPI0715888 A BR PI0715888A BR PI0715888 A2 BRPI0715888 A2 BR PI0715888A2
Authority
BR
Brazil
Prior art keywords
warm
cancer
blooded animal
compound
effect
Prior art date
Application number
BRPI0715888-2A2A
Other languages
English (en)
Inventor
Heather Mary Ellen Duggan
Frederic Georges Marie Leroux
Karine Malagu
Niall Morrisson Barr Martin
Keith Allan Menear
Graeme Cameron Murray Smith
Original Assignee
Kudos Pharm Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38537521&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0715888(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Kudos Pharm Ltd filed Critical Kudos Pharm Ltd
Publication of BRPI0715888A2 publication Critical patent/BRPI0715888A2/pt
Publication of BRPI0715888A8 publication Critical patent/BRPI0715888A8/pt
Publication of BRPI0715888B1 publication Critical patent/BRPI0715888B1/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/53771,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D475/00Heterocyclic compounds containing pteridine ring systems
    • C07D475/06Heterocyclic compounds containing pteridine ring systems with a nitrogen atom directly attached in position 4
    • C07D475/08Heterocyclic compounds containing pteridine ring systems with a nitrogen atom directly attached in position 4 with a nitrogen atom directly attached in position 2
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D475/00Heterocyclic compounds containing pteridine ring systems
    • C07D475/06Heterocyclic compounds containing pteridine ring systems with a nitrogen atom directly attached in position 4
    • C07D475/10Heterocyclic compounds containing pteridine ring systems with a nitrogen atom directly attached in position 4 with an aromatic or hetero-aromatic ring directly attached in position 2

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
BRPI0715888-2A 2006-08-23 2007-08-21 Composto ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, e, uso de um composto BRPI0715888B1 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US82331106P 2006-08-23 2006-08-23
US60/823,311 2006-08-23
US93877607P 2007-05-18 2007-05-18
US60/938,776 2007-05-18
PCT/GB2007/003179 WO2008023161A1 (en) 2006-08-23 2007-08-21 2-methylmorpholine pyrido-, pyrazo- and pyrimido-pyrimidine derivatives as mtor inhibitors

Publications (3)

Publication Number Publication Date
BRPI0715888A2 true BRPI0715888A2 (pt) 2013-09-17
BRPI0715888A8 BRPI0715888A8 (pt) 2018-04-17
BRPI0715888B1 BRPI0715888B1 (pt) 2021-11-03

Family

ID=38537521

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0715888-2A BRPI0715888B1 (pt) 2006-08-23 2007-08-21 Composto ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, e, uso de um composto

Country Status (29)

Country Link
US (6) US7902189B2 (pt)
EP (1) EP2057156B1 (pt)
JP (2) JP5227321B2 (pt)
KR (1) KR101438245B1 (pt)
AR (1) AR062503A1 (pt)
AU (1) AU2007287430B2 (pt)
BR (1) BRPI0715888B1 (pt)
CA (1) CA2659851C (pt)
CL (1) CL2007002448A1 (pt)
CO (1) CO6150164A2 (pt)
CY (1) CY1119381T1 (pt)
DK (1) DK2057156T3 (pt)
ES (1) ES2648388T3 (pt)
HR (1) HRP20170627T1 (pt)
HU (1) HUE033894T2 (pt)
IL (1) IL196775A (pt)
LT (1) LT2057156T (pt)
MX (1) MX2009001946A (pt)
MY (1) MY148688A (pt)
NO (1) NO342383B1 (pt)
NZ (1) NZ575672A (pt)
PL (1) PL2057156T3 (pt)
PT (1) PT2057156T (pt)
RS (1) RS55881B1 (pt)
RU (1) RU2445312C2 (pt)
SA (1) SA07280461B1 (pt)
SI (1) SI2057156T1 (pt)
TW (1) TWI406863B (pt)
WO (1) WO2008023161A1 (pt)

Families Citing this family (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69638122D1 (de) * 1996-09-04 2010-03-18 Intertrust Tech Corp Zuverlässige Infrastrukturhilfssysteme, Verfahren und Techniken für sicheren elektronischen Handel, elektronische Transaktionen, Handelsablaufsteuerung und Automatisierung, verteilte Verarbeitung und Rechteverwaltung
DK2057156T3 (en) * 2006-08-23 2017-05-08 Kudos Pharm Ltd 2-METHYLMORPHOLINPYRIDO, PYRAZO AND PYRIMIDO-PYRIMIDINE DERIVATIVES AS MTOR INHIBITORS
KR20100089082A (ko) * 2007-10-15 2010-08-11 아스트라제네카 아베 조합 059
JP2011512395A (ja) * 2008-02-21 2011-04-21 アストラゼネカ アクチボラグ 組合せ療法238
MY172107A (en) * 2008-06-20 2019-11-14 Astrazeneca Ab Compositions with and process for methylmorpholin-substituted pyrido [2,3-d] pyrimidines
UA101676C2 (uk) * 2008-07-31 2013-04-25 Дженентек, Инк. Піримідинові сполуки, композиції і способи застосування
BRPI0917540A2 (pt) 2008-08-05 2015-11-17 Daiichi Sankyo Co Ltd composto, sal farmacologicamente aceitavél, composição farmacêutica, e, uso de um composto ou sal farmacologicamente aceitável
TWI378933B (en) 2008-10-14 2012-12-11 Daiichi Sankyo Co Ltd Morpholinopurine derivatives
ES2548141T3 (es) 2008-11-20 2015-10-14 Glaxosmithkline Llc Compuestos químicos
ES2570456T3 (es) * 2009-02-12 2016-05-18 Merck Serono Sa 2-Morfolino-pirido[3,2-d]pirimidinas
EP2427174A4 (en) * 2009-05-04 2014-01-15 Santen Pharmaceutical Co Ltd HEMMER OF THE MTOR SIGNAL PATH FOR THE TREATMENT OF EYE TROUBLE
CN102480961A (zh) * 2009-06-24 2012-05-30 健泰科生物技术公司 与含氧杂环稠合的嘧啶化合物、组合物和使用方法
US8242260B2 (en) 2009-08-28 2012-08-14 Novartis Ag Compounds and compositions as protein kinase inhibitors
JP5572715B2 (ja) 2009-11-12 2014-08-13 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト N−7置換プリン及びピラゾロピリミジン化合物、組成物及び使用方法
KR101469334B1 (ko) 2009-11-12 2014-12-04 에프. 호프만-라 로슈 아게 N-9-치환된 퓨린 화합물, 조성물 및 사용 방법
WO2011062939A1 (en) 2009-11-18 2011-05-26 Novartis Ag Methods and compositions for treating solid tumors and other malignancies
WO2011067356A2 (en) 2009-12-03 2011-06-09 Novartis Ag Polymorphs of a mek inhibitor
WO2011067348A2 (en) 2009-12-03 2011-06-09 Novartis Ag Mek inhibitor salts and solvates thereof
CN102821767A (zh) 2010-02-03 2012-12-12 西格诺药品有限公司 Lkb1突变作为对tor激酶抑制剂的敏感性的预测生物标记的鉴定
EP2552428A1 (en) 2010-03-30 2013-02-06 Novartis AG Pkc inhibitors for the treatment of b-cell lymphoma having chronic active b-cell-receptor signalling
JP5918214B2 (ja) 2010-04-13 2016-05-18 ノバルティス アーゲー がんを治療するためのサイクリン依存性キナーゼ4またはサイクリン依存性キナーゼ(cdk4/6)阻害剤およびmtor阻害剤を含む組合せ
CN103080107A (zh) 2010-06-25 2013-05-01 诺瓦提斯公司 作为蛋白激酶抑制剂的杂芳基化合物和组合物
SI2651951T1 (sl) 2010-12-16 2015-01-30 F. Hoffmann-La Roche Ag Tricikliäśne p13k inhibitorske spojine in postopki uporabe
WO2013003801A2 (en) 2011-06-29 2013-01-03 The Trustees Of Columbia University In The City Of New York Inhibitor of neuronal connectivity linked to schizophrenia susceptibility and cognitive dysfunction
MX2014001246A (es) 2011-08-03 2014-06-11 Signal Pharm Llc Identificación del perfil de la expresión génica como biomarcador predictivo del estatus de lkb1.
CN105062961A (zh) 2012-05-23 2015-11-18 弗·哈夫曼-拉罗切有限公司 获得和使用内胚层和肝细胞的组合物和方法
MX2015004016A (es) * 2012-09-28 2016-02-18 Ignyta Inc Inhibidores de azaquinazolina de la proteina quinasa c atipica.
AU2013203714B2 (en) 2012-10-18 2015-12-03 Signal Pharmaceuticals, Llc Inhibition of phosphorylation of PRAS40, GSK3-beta or P70S6K1 as a marker for TOR kinase inhibitory activity
WO2014114928A1 (en) 2013-01-23 2014-07-31 Astrazeneca Ab Chemical compounds
EP2968317A4 (en) * 2013-03-15 2016-12-28 Univ Columbia TARGETING OF THE MTOR PATH IN NEUROLOGICAL DISEASES
CN105392499B (zh) 2013-04-17 2018-07-24 西格诺药品有限公司 用于治疗癌症的包含tor激酶抑制剂和胞苷类似物的组合疗法
WO2014172436A1 (en) 2013-04-17 2014-10-23 Signal Pharmaceuticals, Llc Combination therapy comprising a tor kinase inhibitor and a 5-substituted quinazolinone compound for treating cancer
UA119538C2 (uk) 2013-04-17 2019-07-10 Сігнал Фармасьютікалз, Елелсі Лікування злоякісної пухлини дигідропіразинопіразинами
AU2014254058B2 (en) 2013-04-17 2019-06-06 Signal Pharmaceuticals, Llc Combination therapy comprising a Dihydropyrazino-Pyrazine Compound and an androgen receptor antagonist for treating prostate cancer
AU2014254050B2 (en) 2013-04-17 2018-10-04 Signal Pharmaceuticals, Llc Pharmaceutical formulations, processes, solid forms and methods of use relating to 1-ethyl-7-(2-methyl-6-(1h-1,2,4-triazol-3-yl) pyridin-3-yl) -3,4-dihydropyrazino[2,3-b]pyrazin-2(1h)-one
JP2016516818A (ja) 2013-04-17 2016-06-09 シグナル ファーマシューティカルズ,エルエルシー 癌を治療するためのtorキナーゼ阻害剤及びn−(3−(5−フルオロ−2−(4−(2−メトキシエトキシ)フェニルアミノ)ピリミジン−4−イルアミノ)フェニル)アクリルアミドを含む組合せ療法
US9505764B2 (en) 2013-04-17 2016-11-29 Signal Pharmaceuticals, Llc Treatment of cancer with dihydropyrazino-pyrazines
DE102013008118A1 (de) * 2013-05-11 2014-11-13 Merck Patent Gmbh Arylchinazoline
EP3360875A1 (en) 2013-05-28 2018-08-15 Astrazeneca AB Chemical compounds
CN109503591B (zh) 2013-05-29 2022-03-01 西格诺药品有限公司 二氢吡嗪并吡嗪化合物的药物组合物、其固体形式和它们的用途
US9512129B2 (en) 2014-04-16 2016-12-06 Signal Pharmaceuticals, Llc Solid forms comprising 1-ethyl-7-(2-methyl-6-(1H-1,2,4-triazol-3-yl)pyridin-3-yl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1H)-one and a coformer
NZ714742A (en) 2014-04-16 2017-04-28 Signal Pharm Llc Solid forms of 1-ethyl-7-(2-methyl-6-(1h-1,2,4-triazol-3-yl)pyridin-3-yl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1h)-one, compositions thereof and methods of their use
TWI700283B (zh) * 2014-08-04 2020-08-01 德商拜耳製藥公司 2-(嗎啉-4-基)-1,7-萘啶
CN106008559B (zh) * 2015-03-25 2020-10-16 中国科学院上海药物研究所 取代吡啶并嘧啶类化合物的合成工艺
WO2017031427A1 (en) * 2015-08-19 2017-02-23 3-V Biosciences, Inc. COMPOUNDS AND METHODS FOR INHIBITING mTOR
TW201726140A (zh) 2015-09-17 2017-08-01 瑞典商阿斯特捷利康公司 治療癌症之新型生物標記及方法
DK3889145T3 (da) * 2015-12-17 2024-03-18 Merck Patent Gmbh 8-cyano-5-piperidino-quinoliner som TLR7/8-antagonister og anvendelser deraf til behandling af immunsygdomme
WO2017182495A1 (en) 2016-04-20 2017-10-26 Astrazeneca Ab Indazole derivatives that down-regulate the estrogen receptor and possess anti-cancer activity
TW201803870A (zh) 2016-04-20 2018-02-01 阿斯特捷利康公司 化學化合物
TW201815789A (zh) 2016-07-25 2018-05-01 瑞典商阿斯特捷利康公司 化合物
MX2019013031A (es) 2017-05-02 2020-08-03 Revolution Medicines Inc Análogos de rapamicina como inhibidores de mtor.
CA3067585A1 (en) 2017-06-22 2018-12-27 Celgene Corporation Treatment of hepatocellular carcinoma characterized by hepatitis b virus infection
JP7340519B2 (ja) * 2017-11-06 2023-09-07 メッドシャイン ディスカバリー インコーポレイテッド mTORC1/2二重阻害剤としてのピリドピリミジン系化合物
GB201720989D0 (en) * 2017-12-15 2018-01-31 Glaxosmithkline Ip Dev Ltd Chemical compounds
CA3093189A1 (en) 2018-03-07 2019-09-12 Bayer Aktiengesellschaft Identification and use of erk5 inhibitors
US11471459B2 (en) 2018-03-26 2022-10-18 Fondazione Per L'istituto Oncologico Di Ricerca (Ior) Compounds with enhanced anti-tumor effects
WO2019212990A1 (en) 2018-05-01 2019-11-07 Revolution Medicines, Inc. C40-, c28-, and c-32-linked rapamycin analogs as mtor inhibitors
IL312291A (en) 2018-05-01 2024-06-01 Revolution Medicines Inc C-26-linked rapamycin analogs as MTOR inhibitors
NL2021185B1 (en) 2018-06-26 2020-01-06 Stichting Het Nederlands Kanker Inst Antoni Van Leeuwenhoek Ziekenhuis Combination Therapy and Use Thereof for Treating Cancer
JP2022500384A (ja) 2018-09-10 2022-01-04 ミラティ セラピューティクス, インコーポレイテッド 組み合わせ療法
MX2021004775A (es) 2018-11-05 2021-06-08 Iovance Biotherapeutics Inc Expansion de linfocitos infiltrantes de tumores (tils) usando inhibidores de la via de proteina cinasa b (akt).
CN113286594B (zh) * 2019-01-18 2023-12-15 南京明德新药研发有限公司 吡啶并嘧啶类化合物在制备治疗鼻咽癌药物中的应用
CN113825760B (zh) * 2019-05-06 2022-08-19 南京明德新药研发有限公司 一种mTORC1/2双激酶活性抑制剂的盐型、晶型及其制备方法
WO2021133509A1 (en) * 2019-12-27 2021-07-01 Angex Pharmaceutical, Inc. Heterocyclic compounds as mtor inhibitors
TW202208355A (zh) 2020-05-04 2022-03-01 美商安進公司 作為骨髓細胞觸發受體2促效劑之雜環化合物及使用方法
WO2021226135A1 (en) 2020-05-04 2021-11-11 Amgen Inc. Heterocyclic compounds as triggering receptor expressed on myeloid cells 2 agonists and methods of use
WO2021247859A1 (en) * 2020-06-03 2021-12-09 Yumanity Therapeutics, Inc. Pyridopyrimidines and methods of their use
CA3207998A1 (en) 2021-02-16 2022-08-25 Geoffrey M. Lynn Self-assembling nanoparticles based on amphiphilic peptides
KR20240026911A (ko) * 2021-05-04 2024-02-29 비질 뉴로사이언스 인코포레이티드 골수성 세포 2 작용제 상에서 발현되는 유발 수용체로서의 헤테로고리 화합물 및 사용 방법
WO2023107592A1 (en) * 2021-12-08 2023-06-15 Kineta, Inc. Pyridopyrimidines and methods of their use
WO2024092030A1 (en) 2022-10-25 2024-05-02 Vaccitech North America, Inc. Self-assembling nanoparticles

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS4832899A (pt) 1971-08-28 1973-05-02
US4560685A (en) 1984-06-18 1985-12-24 Dr. Karl Thomae Gesellschaft Mit Beschrankter Haftung 2-Piperazino-pteridines useful as antithrombotics and antimetastatics
DE3445298A1 (de) 1984-12-12 1986-06-12 Dr. Karl Thomae Gmbh, 7950 Biberach Neue pteridine, verfahren zu ihrer herstellung und deren verwendung als zwischenprodukte oder als arzneimittel
WO1996035985A1 (fr) 1995-05-10 1996-11-14 Nintendo Co., Ltd. Systeme de traitement de l'image dans lequel une manette analogique est utilisee
GB9624482D0 (en) * 1995-12-18 1997-01-15 Zeneca Phaema S A Chemical compounds
CZ291386B6 (cs) * 1996-02-13 2003-02-12 Zeneca Limited Chinazolinové deriváty jako inhibitory VEGF, způsob jejich přípravy a farmaceutický prostředek, který je obsahuje
NZ331191A (en) * 1996-03-05 2000-03-27 Zeneca Ltd 4-anilinoquinazoline derivatives and pharmaceutical compositions thereof
GB9718972D0 (en) * 1996-09-25 1997-11-12 Zeneca Ltd Chemical compounds
DK0961780T3 (da) * 1997-02-12 2007-08-27 Electrophoretics Ltd Proteinmarkörer for lungecancer og anvendelse deraf
GB9714249D0 (en) * 1997-07-08 1997-09-10 Angiogene Pharm Ltd Vascular damaging agents
US5990117A (en) * 1998-04-15 1999-11-23 Cell Pathways, Inc. Method for inhibiting neoplastic cells and related conditions by exposure to quinazoline derivatives
GB9900334D0 (en) * 1999-01-07 1999-02-24 Angiogene Pharm Ltd Tricylic vascular damaging agents
GB9900752D0 (en) * 1999-01-15 1999-03-03 Angiogene Pharm Ltd Benzimidazole vascular damaging agents
US7074800B1 (en) * 1999-02-10 2006-07-11 Astrazeneca Ab Quinazoline derivatives as angiogenesis inhibitors
DE50008690D1 (de) 1999-09-07 2004-12-23 Syngenta Participations Ag p-Tolyl-Heterocyclen als Herbizide
CN101219145A (zh) 1999-11-05 2008-07-16 阿斯特拉曾尼卡有限公司 作为vegf抑制剂的喹唑啉衍生物
JP4186355B2 (ja) * 1999-11-24 2008-11-26 株式会社デンソー Csma方式対応無線lan用アンテナ装置及び端末局
DE122008000002I1 (de) * 2000-02-15 2008-04-17 Sugen Inc Pyrrol substituierte indolin-2-on protein kinase inhibitoren
KR100774855B1 (ko) 2000-04-27 2007-11-08 아스텔라스세이야쿠 가부시키가이샤 축합 헤테로아릴 유도체
MXPA02011770A (es) * 2000-05-31 2003-04-10 Astrazeneca Ab Derivados de indol con actividad de dano vascular.
AU2001266232B2 (en) 2000-07-07 2005-09-15 Angiogene Pharmaceuticals Limited Colchinol derivatives as angiogenesis inhibitors
CN1255391C (zh) 2000-07-07 2006-05-10 安吉奥金尼药品有限公司 作为血管破坏剂的colchinol衍生物
US20030187026A1 (en) 2001-12-13 2003-10-02 Qun Li Kinase inhibitors
DE10228103A1 (de) 2002-06-24 2004-01-15 Bayer Cropscience Ag Fungizide Wirkstoffkombinationen
DK1575951T3 (da) 2002-12-06 2014-09-15 Debiopharm Int Sa Heterocykliske forbindelser, fremgangsmåder til fremstilling deraf og deres anvendelse i terapi
ES2290743T3 (es) 2003-04-30 2008-02-16 The Institutes For Pharmaceutical Discovery, Llc Heteroarilos sustituidos como inhibidores de las proteina-tirosina fosfatasas.
EP1769092A4 (en) 2004-06-29 2008-08-06 Europ Nickel Plc IMPROVED LIXIVIATION OF BASE METALS
GB0428475D0 (en) 2004-12-30 2005-02-02 4 Aza Bioscience Nv Pyrido(3,2-D)pyrimidine derivatives and pharmaceutical compositions useful as medicines for the treatment of autoimmune disorders
JP2008531538A (ja) * 2005-02-25 2008-08-14 クドス ファーマシューティカルズ リミテッド 2,4−ジアミノ−ピリドピリミジン誘導体とmTOR阻害剤としてのその使用
MX2007010404A (es) * 2005-02-25 2008-01-11 Kudos Pharm Ltd Hidrazinometilo, hidrazonometilo y compuestos heterociclicos de 5 miembros que actuan como inhibidores de mtor y su uso como agentes anti-cancer.
CA2612788A1 (en) 2005-06-24 2006-12-28 Steven Cesar Alfons De Jonghe Pyrido(3,2-d)pyrimidines and pharmaceutical compositions useful for treating hepatitis c
JP5058991B2 (ja) 2005-06-29 2012-10-24 コンプメディクス リミテッド 導電ブリッジを備えるセンサ・アセンブリ
US20090169472A1 (en) * 2005-10-12 2009-07-02 Cancer Research Technology Ltd. Methods and compositions for treating immune disorders
JP5161102B2 (ja) * 2005-11-22 2013-03-13 クドス ファーマシューティカルズ リミテッド mTOR阻害剤としてのピリドピリミジン、ピラゾピリミジンおよびピリミドピリミジン誘導体
GB0616747D0 (en) * 2006-08-24 2006-10-04 Astrazeneca Ab Novel compounds
DK2057156T3 (en) * 2006-08-23 2017-05-08 Kudos Pharm Ltd 2-METHYLMORPHOLINPYRIDO, PYRAZO AND PYRIMIDO-PYRIMIDINE DERIVATIVES AS MTOR INHIBITORS

Also Published As

Publication number Publication date
JP2013107915A (ja) 2013-06-06
US20140135315A1 (en) 2014-05-15
JP2010501535A (ja) 2010-01-21
RU2009110261A (ru) 2010-09-27
PT2057156T (pt) 2017-05-04
NO20090443L (no) 2009-03-27
US7902189B2 (en) 2011-03-08
RS55881B1 (sr) 2017-08-31
TWI406863B (zh) 2013-09-01
TW200817395A (en) 2008-04-16
NZ575672A (en) 2011-10-28
IL196775A (en) 2017-05-29
AU2007287430B2 (en) 2011-07-21
CA2659851A1 (en) 2008-02-28
HUE033894T2 (en) 2018-01-29
HRP20170627T1 (hr) 2017-06-30
US9717736B2 (en) 2017-08-01
SA07280461B1 (ar) 2012-04-07
MY148688A (en) 2013-05-31
US20080081809A1 (en) 2008-04-03
RU2445312C2 (ru) 2012-03-20
BRPI0715888B1 (pt) 2021-11-03
US10034884B2 (en) 2018-07-31
BRPI0715888A8 (pt) 2018-04-17
AU2007287430A1 (en) 2008-02-28
WO2008023161A1 (en) 2008-02-28
DK2057156T3 (en) 2017-05-08
US20120142673A1 (en) 2012-06-07
NO342383B1 (no) 2018-05-14
JP5629343B2 (ja) 2014-11-19
KR20090042855A (ko) 2009-04-30
US20110124638A1 (en) 2011-05-26
CO6150164A2 (es) 2010-04-20
EP2057156B1 (en) 2017-02-01
EP2057156A1 (en) 2009-05-13
JP5227321B2 (ja) 2013-07-03
SI2057156T1 (sl) 2017-06-30
IL196775A0 (en) 2009-11-18
CL2007002448A1 (es) 2008-05-16
LT2057156T (lt) 2017-05-25
KR101438245B1 (ko) 2014-09-04
CY1119381T1 (el) 2018-02-14
MX2009001946A (es) 2009-03-05
US8435985B2 (en) 2013-05-07
US9102670B2 (en) 2015-08-11
US8101602B2 (en) 2012-01-24
ES2648388T3 (es) 2018-01-02
CA2659851C (en) 2014-02-25
PL2057156T3 (pl) 2017-08-31
US20160067258A1 (en) 2016-03-10
US20170281637A1 (en) 2017-10-05
AR062503A1 (es) 2008-11-12

Similar Documents

Publication Publication Date Title
BRPI0715888A2 (pt) composto ou sal farmaceuticamente aceitÁvel do mesmo, composiÇço farmacÊutica, uso de um composto, e, mÉtodos para produzir um efeito inibitàrio de mtor e um efeito anti-cÂncer em um animal de sangue quente e para tratar doenÇas em um animal de sangue quente
BRPI0821274A2 (pt) composto ou um sal, ou pró-droga farmaceuticamente aceitável do mesmo, uso do mesmo, método para tratar uma doença em um animal de sangue quente, e, composição farmacêutica
BRPI0617241A2 (pt) composto ou um sal ou solvato do mesmo, composição farmacêutica, método para tratar uma doença ou condição mediada por atividade syk inadequada em um mamífero, e, uso de um composto ou um sal ou solvato farmaceuticamente aceitável do mesmo
BRPI0814688A2 (pt) composto, uso de um composto, métodos para produzir um efeito antiproliferativo em um animal de sangue quente, e para tratar doenças, e, composição farmacêutica
BRPI0814503A2 (pt) composto, uso de um composto, métodos para produzir um efeito anti-proliferativo em um animal de sangue quente, e para tratar uma doença, e, composição farmacêutica
BRPI0818244A2 (pt) Composto, composição farmacêutica, uso de um composto, e, método para tratamento de um distúrbio ou doença
BRPI0811534A2 (pt) Composto ou um sal farmaceuticamente aceitável do mesmo, uso de um composto ou um sal farmaceuticamente aceitável do mesmo, método para tratar câncer em um animal de sangue quente, composição farmacêutica, e, processo para preparar um composto ou um sal farmaceuticametne aceitável do mesmo.
BRPI0812851A2 (pt) Composto, composição farmacêutica, métodos para o tratamento de uma doença e de uma condição em um indivíduo, processo para preparar um composto, e, uso de um composto
BRPI0811542A2 (pt) Composto, formulação farmacêutica, uso de um composto, e, métodos para inibir a atividade de bace, e para tratar ou prevenir uma patologia relacionada com abeta em um mamífero composto, formulação farmacêutica, uso de um composto, e, métodos para inibir a atividade de bace, e, para tratar ou prevenir uma patologia relacionada com abeta em um mamífero
BRPI0913212A2 (pt) composto de carbinol, remédio, regulador de lxr, composição farmacêutica, método para prevenir e/ou tratar doença, e, uso do derivado de carbinol ou sal do mesmo, ou seu solvato
BRPI0615157A2 (pt) composto, composição farmacêutica, métodos para inibir a replicação viral em um paciente humano, e para tratar uma infecção viral em um paciente humano, e, uso de um composto
BRPI0818193A2 (pt) composto, sal farmacêuticamente aceitável de um composto, composição farmacêutica, e, uso de um composto
BRPI0607775A2 (pt) conjugado, composição farmacêutica, uso de um composto, e, método para o tratamento ou prevenção de doença
BRPI1004899A2 (pt) composto, composição farmacêutica, método para tratar uma doença ou distúrbio relacionado a pi3k em um indivíduo necessitando do mesmo, método para tratar uma doença mediada por mtor, método para tratar ambas as doenças mediadas por pi3k e hdac
BRPI0618845A2 (pt) composto, formulação farmacêutica, uso de um composto, e, métodos para a inibição da atividade de bace e para o tratamento ou a prevenção de uma patologia relacionada a abeta em um mamífero
BRPI0816097A2 (pt) composição farmacêutica, método para tratar eritema em um paciente com rosácea, e, uso de uma composição.
BRPI0907974A2 (pt) Composto, composição farmacêutica, uso de um composto, e, método para tratar ou prevenir doenças
BRPI1009381A2 (pt) compostos, composição farmacêutica, método para tratar doença ou condição associada com função de trap1 em sujeito em necessidade do mesmo e uso de compostos e composição farmacêutica
BRPI0912348A2 (pt) composto de 3-aminocarbazol, composição farmacêutica, método para preparar um composto de 3-aminocarbazol, uso de um composto de 3-aminocarbazol, e, método para tratar ou prevenir doenças
BRPI0812738A2 (pt) Composto, sal farmceuticamente aceitável, composição farmacêutica, uso de um composto, e, método par ao tratamento de uma infecção viral em um humano
BRPI0712516A2 (pt) compostos, composições farmacêuticas, antagonista receptor de a2b, método para uso terapêutico e/ou tratamento profilático e uso de antagonista receptor de a2b
BRPI0917705A2 (pt) composto, pró-droga, composição farmacêutica, método para tratar ou prevenir uma doença ou condição, e, uso do composto
BRPI0607545A2 (pt) composto, uso de um composto de fórmula i ou um sal farmaceuticamente aceitável do mesmo, e, composição farmacêutica
BRPI0808034A2 (pt) Método para produzir hidrocloreto de prasugrel, hidrocloreto de prasugrel, composição farmacêutica, e, uso de um hidrocloreto de prasugrel.
BRPI0907162A2 (pt) Composto, composição farmacêutica e métodos para ativar procaspase executora 3, 6 e/ou 7 e para tratar um estado de doença em um mamífero

Legal Events

Date Code Title Description
B25G Requested change of headquarter approved

Owner name: KUDOS PHARMACEUTICALS LIMITED (GB)

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06T Formal requirements before examination [chapter 6.20 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 21/08/2007, OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF, QUE DETERMINA A ALTERACAO DO PRAZO DE CONCESSAO.